Abstract:Phenotypic drug discovery (PDD) screens compounds in cellular models that represent disease-relevant phenotypes, offering a compelling alternative to traditional target-based approaches. Unlike conventional methods, where compounds act on a single predefined target, PDD identifies compounds capable of exerting therapeutic effects through multiple targets and mechanisms. This makes PDD particularly valuable for discovering first-in-class drugs, especially for diseases with poorly understood molecular mechanisms or those lacking validated therapeutic targets. By enabling broader exploration of biological systems and uncovering multi-target drugs (polypharmacology), PDD provides a powerful strategy for tackling complex diseases. In this study, we introduce PhenoScreen, a deep learning framework designed to advance PDD by utilizing large-scale compound-phenotype association data. Through contrastive learning, PhenoScreen connects chemical space with cellular morphological profiles, allowing for accurate prediction of compound-induced phenotypic changes. PhenoScreen can also accurately identfiy lead compounds which could induce user defined phenotypic shift but more novel scaffolds using different levels of phenotypic information reflected by diverse compounds. The model was validated across multiple screening tasks and successfully predicted active compounds inducing user-specified phenotypes with varying inhibitory effects in the osteosarcoma phenotypic model. Further, other than showing effectiveness to osteosarcoma, our experiments also showed that PhenoScreen demonstrated strong generalization to rhabdomyosarcoma, and the active compound we screened had an IC50 of up to 6.62 uM, suggesting its ability to capture key phenotypic features shared across cancer cells. These results underscore PhenoScreen's potential to accelerate drug discovery by identifying novel therapeutic pathways and increasing the diversity of viable drug candidates. PhenoScreen is accessible online via our group's web server for compound virtual screening at https://bailab.siais.shanghaitech.edu.cn/services/PhenoScreen/, and the source codes are available at https://github.com/Shihang-Wang-58/PhenoScreen.

Progressive screening using scaffold-based classification approach

Combined strategies in structure-based virtual screening

Assessing the Scaffold Diversity of Screening Libraries

Abstract 3096: CETSA Navigate HT: A new paradigm for high-throughput screening

Virtual Screening of a Chemically Diverse "Superscaffold" Library Enables Ligand Discovery for a Key GPCR Target

Comparative Analyses of Structural Features and Scaffold Diversity for Purchasable Compound Libraries

PhenoScreen: A Dual-Space Contrastive Learning Framework-based Phenotypic Screening Method by Linking Chemical Perturbations to Cellular Morphology

Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening

Machine learning assisted hit prioritization for high throughput screening in drug discovery

An Open-Source Implementation of the Scaffold Identification and Naming System (SCINS) and Example Applications

FSDscore: An Effective Target‐Focused Scoring Criterion for Virtual Screening

The development of high-content screening (HCS) technology and its importance to drug discovery

Efficient Exploration of Chemical Space with Docking and Deep Learning

Scaffold Splits Overestimate Virtual Screening Performance

Completing the Screen: Biochemical Cascades to Prioritize HTS Output

Fully Automated OCT-based Tissue Screening System

Consumption and Saving Problem with Stochastic Interest Rates

Improved Scaffold Hopping in Ligand-based Virtual Screening Using Neural Representation Learning

Recent progress on the prospective application of machine learning to structure-based virtual screening

The Development of Target-Specific Pose Filter Ensembles to Boost Ligand Enrichment for Structure-Based Virtual Screening.